All Posts: pancreatic cancer
-
Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
Category: News Release
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Ruesch Symposium Participants Encourage Patients to Consider Clinical Trials
(December 2, 2022) — After being diagnosed with pancreatic cancer in April 2021, Jan Baird-Adams, a librarian from Maryland, had lots of questions for her oncologist, Marcus Noel, MD, associate professor of oncology and director of the Clinical Research Management Office at Georgetown Lombardi Comprehensive Cancer Center. “Dr. Noel and his staff were incredibly kind […]
Category: Lombardi Stories
-
Experimental Drug Boosts Immunotherapy Effectiveness in Pancreatic Cancer in Mice
WASHINGTON (November 4, 2021) — An experimental drug enhanced the benefit of an immunotherapy to fight pancreatic cancer in mice by increasing the number of immune cells in the immediate vicinity of the tumor, leading to a reduction in tumor growth, and in some mice, eliminating their cancer. The findings, from researchers at Georgetown Lombardi […]
Category: News Release
-
Mechanism for How Pancreatic Cancer Evades Immunotherapy Elucidated
Discovery could lead to new or improved therapeutic options. WASHINGTON (January 28, 2021) — Pancreatic cancer, one of the most lethal of all cancers, is capable of evading attacks by immune cells by changing its microenvironment so that the immune cells suppress, rather than support, an attack on the tumor, according to a study led […]
Category: News Release
-
Disrupting the Cellular Process That Promotes Pancreatic Cancer’s Deadly Growth
WASHINGTON (December 8, 2020) — Researchers say they’ve identified a way to disrupt a process that promotes the growth of pancreatic cancers — one of the most difficult and deadly cancers to treat. The team, led by scientists at Georgetown Lombardi Comprehensive Cancer Center and including investigators from Lawrence Livermore National Laboratories, STCube and Fluidigm, […]
Category: News Release
-
Revealing the Molecular Engine That Drives Pancreatic Cancer Provides Ways to Turn It Off
Researchers at Georgetown Lombardi have decoded a chain of molecules that are critical for the growth and survival of the most common and most lethal form of pancreatic cancer.
Category: News Release
-
Facing a Difficult Diagnosis, Why One Patient Chooses to Confront Cancer at Georgetown Lombardi
When Adam Skipper was diagnosed with pancreatic cancer, he decided to pursue treatment at Georgetown Lombardi Comprehensive Cancer Center rather than a hospital closer to his home.
Category: Lombardi Stories
-
Addressing an ‘Aching Need to do Something’ About Pancreatic Cancer
Jeanne Ruesch received the Margaret L. Hodges Leadership Award at the 31st annual Lombardi Gala on November 18 for her advocacy on behalf of research into pancreatic cancer and other cancers of the GI tract.
Category: Lombardi Stories
-
PanCAN PurpleStride Commemorates Struggles, Triumphs Toward A Cure
June 17, 2016 — “When we first found out about his diagnosis, I told him I would be with him every step of the way,” said Sarah Saleh, whose husband, Rashid, was a Georgetown Lombardi patient. “He said it gave him strength to have me with him.” Many Georgetown Lombardi families at the annual PanCAN […]
Category: Lombardi Stories